Floatz logo

VALSARTAN

Ischemic Heart Disease

Kyoto Prefectural University of MedicineSmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Ischemic Heart Disease cohort.

Asset / SponsorPhaseRating
Ranolazine
East Carolina University
Phase 4A
ATENOLOL
Xintong Pharmacy Company
Phase 4BBB
Acetylsalicylic Acid
Rajaie Cardiovascular Medical and Research Center
Phase 4BBB
Ranolazine
East Carolina University
Phase 4BBB
3-(2,2,2-TRIMETHYLDIAZANIUMYL)PROPANOATE
Burnasyan Federal Medical Biophysical Center
Phase 4BB

View all 35 →

Same molecule, other indications

VALSARTAN is also rated in:

hypertensive disorderDormant
BBB
Indicative ·
77 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
BB
Indicative ·
69 / 100
View asset →
essential hypertensionDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →